Claus Garbe

Summary

Country: Germany

Publications

  1. pmc Systematic review of medical treatment in melanoma: current status and future prospects
    Claus Garbe
    Department of Dermatology, Division of Dermatooncology, University Hospital Tubingen, Liebermeisterstrasse 25, 72076 Tubingen, Germany
    Oncologist 16:5-24. 2011
  2. pmc Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
    P Radny
    Department of Dermatology, Eberhard Karls University, Liebermeistersrasse 20, , Germany
    Br J Cancer 89:1620-6. 2003
  3. pmc Determinants of survival in patients with brain metastases from cutaneous melanoma
    M Staudt
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    Br J Cancer 102:1213-8. 2010
  4. pmc Non-AIDS associated Kaposi's sarcoma: clinical features and treatment outcome
    Lena Jakob
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    PLoS ONE 6:e18397. 2011
  5. doi request reprint Vemurafenib
    Claus Garbe
    Department of Dermatology, University Medical Centre, Liebermeisterstr 25, 72074, Tuebingen, Germany
    Recent Results Cancer Res 201:215-25. 2014
  6. doi request reprint Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012
    Claus Garbe
    University Department of Dermatology, Tuebingen, Germany
    Eur J Cancer 48:2375-90. 2012
  7. doi request reprint Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:61-7. 2008
  8. ncbi request reprint Epidemiology of cutaneous melanoma in Germany and worldwide
    C Garbe
    Department of Dermatology, University of Tubingen, Germany
    Skin Pharmacol Appl Skin Physiol 14:280-90. 2001
  9. ncbi request reprint [Therapy of malignant melanoma at the stage of distant metastasis]
    C Garbe
    Sektion Dermatologische Onkologie, Universitäts Hautklinik, Eberhard Karls Universitat, Tubingen
    Hautarzt 55:195-213. 2004
  10. doi request reprint Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
    C Garbe
    Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University of Tubingen, Tubingen, Germany
    Ann Oncol 19:1195-201. 2008

Detail Information

Publications159 found, 100 shown here

  1. pmc Systematic review of medical treatment in melanoma: current status and future prospects
    Claus Garbe
    Department of Dermatology, Division of Dermatooncology, University Hospital Tubingen, Liebermeisterstrasse 25, 72076 Tubingen, Germany
    Oncologist 16:5-24. 2011
    ....
  2. pmc Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
    P Radny
    Department of Dermatology, Eberhard Karls University, Liebermeistersrasse 20, , Germany
    Br J Cancer 89:1620-6. 2003
    ..The optimal dosage and duration of this therapy still remain to be defined in larger prospective multicentre trials...
  3. pmc Determinants of survival in patients with brain metastases from cutaneous melanoma
    M Staudt
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    Br J Cancer 102:1213-8. 2010
    ..This retrospective study aimed to identify prognostic factors in patients with brain metastases from cutaneous melanoma...
  4. pmc Non-AIDS associated Kaposi's sarcoma: clinical features and treatment outcome
    Lena Jakob
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    PLoS ONE 6:e18397. 2011
    ..Two groups are at risk to develop non-AIDS related KS: elderly men mainly of Mediterranean origin and persons with iatrogenic immunosuppression...
  5. doi request reprint Vemurafenib
    Claus Garbe
    Department of Dermatology, University Medical Centre, Liebermeisterstr 25, 72074, Tuebingen, Germany
    Recent Results Cancer Res 201:215-25. 2014
    ..In future, combinations of vemurafenib with other kinase inhibitors and with immunotherapies will improve its therapeutic potential. ..
  6. doi request reprint Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012
    Claus Garbe
    University Department of Dermatology, Tuebingen, Germany
    Eur J Cancer 48:2375-90. 2012
    ..Therapeutic decisions in stage IV patients should be primarily made by an interdisciplinary oncology team ('tumour board')...
  7. doi request reprint Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:61-7. 2008
    ..In distant metastases, radiation therapy is particularly indicated in bone metastases, brain metastases and soft tissue metastases...
  8. ncbi request reprint Epidemiology of cutaneous melanoma in Germany and worldwide
    C Garbe
    Department of Dermatology, University of Tubingen, Germany
    Skin Pharmacol Appl Skin Physiol 14:280-90. 2001
    ..This development indicates improved early recognition of cutaneous melanoma which is presently the main factor for a more favorable prognosis...
  9. ncbi request reprint [Therapy of malignant melanoma at the stage of distant metastasis]
    C Garbe
    Sektion Dermatologische Onkologie, Universitäts Hautklinik, Eberhard Karls Universitat, Tubingen
    Hautarzt 55:195-213. 2004
    ..Effective cancer vaccination strategies and blockade of melanoma specific target molecules are currently developed as new treatment options...
  10. doi request reprint Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
    C Garbe
    Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University of Tubingen, Tubingen, Germany
    Ann Oncol 19:1195-201. 2008
    ..The aim of the study was to improve disease-free survival (DFS) and overall survival (OS) with interferon (IFN) alpha2a with or without dacarbazine (DTIC) compared with observation alone...
  11. ncbi request reprint Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy
    Claus Garbe
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University of Tuebingen, Germany
    J Clin Oncol 21:520-9. 2003
    ..To prospectively examine and evaluate the results of follow-up procedures in a large cohort of cutaneous melanoma patients...
  12. ncbi request reprint Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients
    Claus Garbe
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    Cancer 97:1737-45. 2003
    ....
  13. doi request reprint Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
    Claus Garbe
    Center for Dermatooncology, Department of Dermatology, 72076 Tubingen, Germany
    Eur J Cancer 46:270-83. 2010
    ..In the absence of surgical options, systemic medical treatment is indicated, but with, to date, low response rates. Therapeutic decisions should be made by the melanoma team and the informed patient after full discussion of the options...
  14. doi request reprint Melanoma epidemiology and trends
    Claus Garbe
    Division of Dermato oncology, Eberhard Karls University, 72076 Tuebingen, Germany
    Clin Dermatol 27:3-9. 2009
    ..This development indicates improved early recognition of cutaneous melanoma, which is presently the main factor for a more favorable prognosis...
  15. doi request reprint Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:152-60. 2008
    ..An urgent need for development of new treatment modalities is necessary and general principles of experimental immunotherapy are outlined...
  16. doi request reprint Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice
    Claus Garbe
    Department of Dermatology, Tubingen University Hospital, Germany
    J Dtsch Dermatol Ges 9:690-9. 2011
    ..Conclusions: These recommendations are suitable for standardizing the histopathological diagnosis of malignant melanoma and for providing a common basis for clinical decisions and scientific research...
  17. ncbi request reprint Cutaneous melanoma: baseline and ongoing laboratory evaluation
    Claus Garbe
    Division of Dermato oncology, Department of Dermatology, University of Tubingen, Germany
    Dermatol Ther 18:413-21. 2005
    ..Early detection of limited disease using these methods may be helpful for patients who have locoregional metastases and for 10-20% of patients who have distant metastases and whose limited disease may be amenable to surgical resection...
  18. ncbi request reprint [Brief guidelines: malignant melanoma of the skin]
    Claus Garbe
    Universitäts Hautklinik Tübingen
    J Dtsch Dermatol Ges 4:344-9. 2006
  19. ncbi request reprint Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 17:393-9. 2007
    ..Additionally, in the stage of regional metastasis, whole body imaging should be performed every 6 months; in the stage of distant metastasis, surveillance has to be scheduled individually...
  20. ncbi request reprint Diagnosis and treatment of cutaneous melanoma: state of the art 2006
    Claus Garbe
    Division of Dermatooncology, Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    Melanoma Res 17:117-27. 2007
    ..A number of new treatment modalities, including targeted molecules and immunologic approaches with monoclonal antibodies, are under development; hopefully, new treatment modalities will be available in the near future...
  21. ncbi request reprint Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry
    Thomas K Eigentler
    Department of Dermatology, Eberhard Karls University, D 72076 Tuebingen, Germany
    J Clin Oncol 22:4376-83. 2004
    ..The present study was performed to validate the prognostic significance of ulceration in relation to T thickness and clinical stages of CM (stages I to III)...
  22. doi request reprint Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
    Benjamin Weide
    Department of Dermatology, Division of Dermatooncology, University of Tubingen, Tubingen, Germany
    J Immunother 32:498-507. 2009
    ....
  23. doi request reprint Age and gender are significant independent predictors of survival in primary cutaneous melanoma
    Konstantinos Lasithiotakis
    Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Central Malignant Melanoma Registry of the German Dermatological Society, Tuebingen, Germany
    Cancer 112:1795-804. 2008
    ..The aim was to identify age- related and gender-related differences in the clinical presentation and outcome of patients with primary cutaneous melanoma (CM)...
  24. doi request reprint Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement
    Ulrike Leiter
    Department of Dermatology, Eberhard Karls University, Center for Dermato Oncology, Tuebingen, Germany
    Ann Surg Oncol 17:129-37. 2010
    ..However, the potential survival benefit of SLND is still controversial...
  25. doi request reprint Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group
    Thomas K Eigentler
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany
    Melanoma Res 18:353-8. 2008
    ..Thus, this randomized trial did not confirm earlier reports of beneficial effects of adjuvant vindesine and can therefore not be recommended...
  26. doi request reprint Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial
    Maja A Hofmann
    Department of Dermatology, Charite Universitatsmedizin, Berlin, Germany
    Melanoma Res 21:516-23. 2011
    ..Interestingly, having the choice of chemotherapy or BSC alone in a second-line situation, more than 70% of patients chose polychemotherapy...
  27. ncbi request reprint Melanoma staging: facts and controversies
    Andrea Forschner
    Center for Dermato Oncology, Department of Dermatology, University Hospital Tubingen, 72076 Tubingen, Germany
    Clin Dermatol 28:275-80. 2010
    ..The risk of recurrence or tumor progression is very high in stage IV patients, and their management is individualized...
  28. doi request reprint Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide
    Tobias Sinnberg
    Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany
    J Invest Dermatol 129:1500-15. 2009
    ..These effects were associated with suppression of the antiapoptotic Bcl-2 family protein Mcl-1. These data suggest that inhibition of the PI3K-AKT-mTOR pathway potently increases sensitivity of melanoma cells to chemotherapy...
  29. doi request reprint Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
    Benjamin Weide
    Department of Dermatology, Center of Dermatooncology, University of Tubingen, Liebermeisterstr 25, 72076, Tubingen, Germany
    Cancer Immunol Immunother 60:487-93. 2011
    ..Furthermore, the intratumoral IL-2 treatment seemed to be associated with increased complete and partial responses in subsequent chemotherapies...
  30. pmc Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour
    Benjamin Weide
    Center for Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany
    PLoS ONE 8:e66953. 2013
    ....
  31. doi request reprint The role of radiotherapy in the overall treatment of melanoma
    Andrea Forschner
    Department of Dermatology, University Hospital Tubingen, Tubingen, Germany
    Clin Dermatol 31:282-9. 2013
    ..We review several indications for radiotherapy in the management of malignant melanoma with an effect on the guidelines in our clinical practice...
  32. pmc Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma
    Annette Pflugfelder
    Department of Dermatology, Center for Dermatooncology, University Hospital Tuebingen, Tuebingen, Germany
    PLoS ONE 6:e16882. 2011
    ..Based on previous promising experiences within a clinical trial involving carboplatin and paclitaxel a series of advanced metastatic melanoma patients were treated with this combination...
  33. ncbi request reprint Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin
    Christian Busch
    Section of Dermatologic Oncology, Department of Dermatology, University of Tubingen, Germany
    Int J Oncol 31:1367-78. 2007
    ....
  34. pmc Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
    Heike Niessner
    Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen Germany
    Cancer Med 2:76-85. 2013
    ..Thus, inhibition of PI3K-AKT signaling shows potential for enhancing and/or prolonging the antitumor effect of BRAF inhibitors or other anticancer agents in melanoma brain metastases...
  35. doi request reprint High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma
    Benjamin Weide
    Department of Dermatology, Center of Dermato Oncology, University of Tuebingen, Tuebingen, Germany
    Cancer 116:4139-46. 2010
    ..The objectives of the current study were to confirm those results in a larger cohort and to identify patient or regimen characteristics associated with response...
  36. pmc Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany
    PLoS ONE 8:e63137. 2013
    ....
  37. doi request reprint The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells
    Heike Niessner
    Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany
    J Invest Dermatol 131:468-79. 2011
    ..Together, these findings suggest that the FTI lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells and may therefore represent an effective alternative for melanoma treatment...
  38. ncbi request reprint Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed?
    Konstantinos G Lasithiotakis
    Division of Dermatologic Oncology, Department of Dermatology, Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard Karls University, Tuebingen, Germany
    Cancer 109:1174-82. 2007
    ..A hypothesis generated a retrospective analysis of the improvement of survival over time in patients with cutaneous melanoma (CM) in order to identify factors contributing to this progress...
  39. ncbi request reprint Incisional biopsy and melanoma prognosis: Facts and controversies
    Annette Pflugfelder
    Center for Dermatooncology, Department of Dermatology, University Hospital Tubingen, Liebermeisterstr 25, 72076 Tubingen, Germany
    Clin Dermatol 28:316-8. 2010
    ..Incisional biopsies of malignant melanoma do not negatively influence prognosis. Complete excision of primary melanoma is still the recommended standard of care and is a precondition for accurate histopathologic diagnosis...
  40. ncbi request reprint Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies
    Ulrike Leiter
    Center of Dermato Oncology, Department of Dermatology, University of Tuebingen, Liebermeisterstr 25, 72076 Tuebingen, Germany
    Clin Dermatol 28:311-5. 2010
    ..Whereas the treatment for primary melanoma is accepted world wide, follow-up strategies for melanoma patients are discussed controversially, and so far, no international consensus has been reached...
  41. ncbi request reprint The adhesion molecule L1 (CD171) promotes melanoma progression
    Friedegund Meier
    Department of Dermatology, Section of Dermatologic Oncology, University of Tuebingen, Tuebingen, and Tumor Immunology Programme, German Cancer Research Center, Heidelberg, Germany
    Int J Cancer 119:549-55. 2006
    ..Altogether, L1 plays a critical role in melanoma invasion and progression and offers therapeutic potential in combination with conventional anticancer agents...
  42. doi request reprint Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?
    Ulrike Leiter
    Center of Dermato Oncology, Eberhard Karls University, Tuebingen, Germany
    Melanoma Res 20:240-6. 2010
    ..The classification of metastasis detected in early and advanced phase may be used in future studies aiming to improve melanoma surveillance...
  43. doi request reprint Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
    Friedegund Meier
    Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Liebermeisterstr 25, Tubingen D 72076, Germany
    J Am Acad Dermatol 60:863-8. 2009
    ..Our case report, together with the literature discussed, suggests that mTOR inhibition possibly enhances the sensitivity of melanoma cells to chemotherapy and should prompt in-depth and clinical investigation...
  44. ncbi request reprint Proliferative activity, chromosomal aberrations, and tumor-specific mutations in the differential diagnosis between blue nevi and melanoma
    Laura Held
    Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany
    Am J Pathol 182:640-5. 2013
    ..Patients with histologically ambiguous dermal melanocytic proliferations that exhibit copy number aberrations should undergo careful clinical follow-up...
  45. doi request reprint Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome
    Laura Held
    Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany
    J Cutan Pathol 39:1088-93. 2012
    ..This case shows that nodules in plaque-type blue nevus may have malignant potential which may be uncovered by CGH...
  46. pmc Prognosis of sentinel node staged patients with primary cutaneous melanoma
    Otmar Elsaesser
    Center for Dermatooncology, Department of Dermatology, and Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    PLoS ONE 7:e29791. 2012
    ....
  47. pmc β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance
    Tobias Sinnberg
    Division of Dermatooncology, Department of Dermatology, Eberhard Karls University Tubingen, Tubingen, Germany
    PLoS ONE 6:e23429. 2011
    ..The differential requirements for beta-catenin signaling in aggressive melanoma versus benign melanocytic cells make beta-catenin a possible new target in melanoma therapy...
  48. ncbi request reprint Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care
    Jurgen Bauer
    Department of Dermatology, Faculty of Medicine, Eberhard Karls University, Tubingen, Germany
    Am J Epidemiol 161:620-7. 2005
    ..Randomized controlled trials are needed to confirm these results. Meanwhile, public education should aim to protect children primarily by sun avoidance and protective clothing, while sunscreen should also be used...
  49. ncbi request reprint The natural course of cutaneous melanoma
    Ulrike Leiter
    Department of Dermatology, Division of Dermatologic Oncology, Eberhard Karls University, Tuebingen, Germany
    J Surg Oncol 86:172-8. 2004
    ....
  50. doi request reprint Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients
    Liljana Mervic
    Department of Dermatology, Center of Dermatooncology, University of Tubingen, Germany
    Melanoma Res 21:244-52. 2011
    ..A female survival advantage is also known for other solid tumors such as colon and lung cancer; however, age dependency has not been studied...
  51. ncbi request reprint Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group
    Roland Kaufmann
    Department of Dermatology, J W Goethe University, Frankfurt am Main, Germany
    J Clin Oncol 23:9001-7. 2005
    ....
  52. ncbi request reprint Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites
    Siegbert Rieg
    Department of Dermatology, Eberhard Karls University Tubingen, Tubingen, Germany
    J Invest Dermatol 126:354-65. 2006
    ..Owing to the durable and abundant presence, DCD-derived peptides contribute to the first line of defense by building a constant barrier that overlies the epithelial skin...
  53. ncbi request reprint The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003
    Konstantinos G Lasithiotakis
    Section of Dermatological Oncology, Department of Dermatology, Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard Karls University, Tuebingen, Germany
    Cancer 107:1331-9. 2006
    ..Detailed, long-term trends of CM in relation to clinical and pathologic characteristics in a Central European population have not been published to date...
  54. doi request reprint Oncogenetics of melanoma: basis for molecular diagnostics and therapy
    Laura Held
    Department of Dermatology, University of Tubingen, Germany
    J Dtsch Dermatol Ges 9:510-6. 2011
    ..The present article reviews signaling pathways in melanocytes and alterations in melanoma that are a prerequisite to understanding modern cancer therapies in melanoma...
  55. doi request reprint A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma
    Thomas K Eigentler
    Department of Dermatology, University Medical Center, Tubingen, Germany
    Clin Cancer Res 17:7732-42. 2011
    ..5 million international units (Mio IU) IL2 equivalents. In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma...
  56. doi request reprint Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry
    Ulrike Leiter
    Center for Dermato Oncology, Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    J Am Acad Dermatol 66:37-45. 2012
    ..Knowledge about the risk for recurrence and secondary cutaneous melanoma (CM) is an important basis for patient counseling and planning of follow-up examinations...
  57. doi request reprint Distribution of muscarinic receptor subtype M3 in melanomas and their metastases
    Matthias Oppitz
    Section of Dermatologic Oncology, Department of Dermatology, University of Tubingen, Tubingen, Germany
    J Cutan Pathol 35:809-15. 2008
    ..To substantiate the experimental data, here the correlation of mR-expression with invasive growth was studied on the cellular level by comparison with HMB-45 immunoreactivity...
  58. pmc BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy
    Diana Meckbach
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tubingen, Germany
    PLoS ONE 9:e89218. 2014
    ..The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial...
  59. doi request reprint Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"
    Annette Pflugfelder
    Department of Dermatology, University Hospital Tubingen, Germany
    J Dtsch Dermatol Ges 11:1-116, 1-126. 2013
    ..Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years...
  60. doi request reprint Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
    Benjamin Weide
    University Medical Center, University of Tubingen, Tubingen, Germany
    J Clin Oncol 30:1835-41. 2012
    ..To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis...
  61. doi request reprint Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight
    Ulrike Leiter
    Division of Dermatoloncology, Department of Dermatology, University Medical Center, University of Tuebingen, Liebermeisterstr, 25, 72076 Tuebingen, Germany
    Adv Exp Med Biol 624:89-103. 2008
    ..In contrast to squamous cell carcinoma, melanoma risk seems not to be associated with cumulative, but intermittent exposure to sunlight. Therefore campaigns for prevention and early detection are necessary...
  62. ncbi request reprint The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance
    Birgit Schittek
    Division of Dermatologic Oncology, Department of Dermatology, University of Tubingen, Liebermeisterstrasse 25, D 72076 Tubingen, Germany
    Int J Cancer 120:2110-8. 2007
    ..Thus, YB-1 may be a promising molecular target in melanoma therapy...
  63. doi request reprint Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
    Axel Hauschild
    Department of Dermatology, University of Kiel bCharité University Medicine Berlin, Germany
    Melanoma Res 18:274-8. 2008
    ..Single-agent treatment with MS-275 was well-tolerated and showed long-term tumor stabilizations, but no objective responses in pretreated metastatic melanoma. Further evaluation of MS-275 in combination schedules is warranted...
  64. ncbi request reprint Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior
    Jurgen Bauer
    Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    Int J Cancer 116:755-61. 2005
    ..High prevalence of sunscreen use at study commencement, social desirability, and inadequate application of sunscreens might have partially covered their effect...
  65. ncbi request reprint A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma
    Thomas K Eigentler
    Skin Cancer Program, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    J Am Acad Dermatol 57:616-21. 2007
    ..The present study was planned to evaluate the efficacy and tolerability of topical treatment with imiquimod in nodular basal cell carcinoma (nBCC)...
  66. doi request reprint Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
    Benjamin Weide
    Department of Dermatology, Institute for Cell Biology, University of Tubingen, Germany
    J Immunother 31:180-8. 2008
    ..However, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumor immunotherapy was not shown in this study and must be evaluated in subsequent trials...
  67. ncbi request reprint Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society
    Ulrike Leiter
    Department of Dermatology, Central Malignant Melanoma Registry of the Germany Dermatological Society, Eberhard Karls University, Tuebingen, Germany
    J Clin Oncol 22:3660-7. 2004
    ..The aim of the present study was to identify prognostic factors in thin CM...
  68. ncbi request reprint Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children
    Jurgen Bauer
    Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    Int J Cancer 115:121-6. 2005
    ..Public health education should focus primarily on avoiding sun exposure especially in children with fair skin and parents with high nevus counts...
  69. doi request reprint Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis
    Tobias Sinnberg
    Department of Dermatology, Eberhard Karls University Tubingen, Tubingen, Germany
    Cancer Res 70:6999-7009. 2010
    ..These results show that melanoma cells developed an efficient new mechanism to activate the beta-catenin signaling pathway and define CK1alpha as a novel tumor suppressor...
  70. ncbi request reprint New promises in the adjuvant, and palliative treatment of melanoma
    Axel Hauschild
    Department of Dermatology, University of Kiel, Kiel, Germany
    Cancer Treat Res 135:277-92. 2007
  71. doi request reprint Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
    Konstantinos G Lasithiotakis
    Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany
    J Invest Dermatol 128:2013-23. 2008
    ..Sorafenib combined with rapamycin appears to be a promising strategy for the effective treatment of melanoma and merits clinical investigation...
  72. doi request reprint Management of primary and metastasized melanoma in Germany in the time period 1976-2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society
    Silke S Schwager
    Department of Dermatology, Skin Cancer Program, Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    Melanoma Res 18:112-9. 2008
    ..Management of metastasized melanoma showed a tendency towards surgical procedures in limited disease and an ongoing trend to systemic treatment in advanced disease...
  73. doi request reprint Costs of the detection of metastases and follow-up examinations in cutaneous melanoma
    Ulrike Leiter
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tubingen 72076, Germany
    Melanoma Res 19:50-7. 2009
    ..6% in stage III). A risk-adapted surveillance strategy for stage I-II including thorough history, physical examination and lymph node sonography but omitting CR, blood work and abdomen sonography, seems appropriate and cost effective...
  74. ncbi request reprint Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L
    Daniel Baechle
    Medical and Natural Sciences Research Center, University of Tubingen, Ob dem Himmelreich 7, 72074 Tubingen, Germany
    J Biol Chem 281:5406-15. 2006
    ..Functional analysis indicated that proteolytic processing of DCD-1L by CatD in human sweat modulates the innate immune defense of human skin...
  75. ncbi request reprint Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
    Thomas K Eigentler
    Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    Lancet Oncol 4:748-59. 2003
    ..Systemic treatments should preferably be investigated in randomised trials so that the potential benefits of new treatment concepts can be thoroughly examined...
  76. ncbi request reprint Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma
    Christian Müller-Horvat
    Department of Diagnostic Radiology, Eberhard Karls University, Tubingen, Germany
    Eur J Cancer 42:342-50. 2006
    ..More accurate and complete staging by wbMRI has an impact on treatment strategy in about one-quarter of the patients...
  77. doi request reprint Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009
    Anne F Pfeil
    Center of Dermato Oncology, Eberhard Karls University, Tuebingen, Germany
    Melanoma Res 21:228-34. 2011
    ..Patients with MUP can be classified according to AJCC, which presented as the strongest prognostic factor. From a management perspective it is important to notice that the majority of MUP were classified as stage III...
  78. doi request reprint Extramammary Paget's disease: extended subclinical growth detected using three-dimensional histology in routine paraffin procedure and course of the disease
    Alexandra Boehringer
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    Dermatol Surg 37:1417-26. 2011
    ..Extramammary Paget's disease (EMPD) is a rare tumor of the skin characterized by extended irregular subclinical growth and high recurrence rates after surgery...
  79. ncbi request reprint Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma
    Christina Pfannenberg
    Department of Diagnostic Radiology, Eberhard Karls University Tuebingen, Hoppe Seyler Strasse 3, 72076 Tuebingen, Germany
    Eur J Cancer 43:557-64. 2007
    ..In 41 patients (64%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol...
  80. ncbi request reprint Imiquimod in the treatment of extensive recurrent lentigo maligna
    Anne Kamin
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany
    J Am Acad Dermatol 52:51-2. 2005
    ..Clinically and histologically, a complete clearing of the lesion was observed after treatment. Topical treatment with imiquimod seems to be effective and safe in lentigo maligna...
  81. ncbi request reprint Melanoma of the ear: prognostic factors and surgical strategies
    V Jahn
    Department of Dermatology, University of Tuebingen Clinics, Eberhard Karls Universitat, Liebermeisterstr 25, D 72076 Tuebingen, Germany
    Br J Dermatol 154:310-8. 2006
    ..The ear's specific anatomical and lymphatic characteristics impose special requirements on the treatment of melanoma of the ear...
  82. ncbi request reprint A rational approach to the follow-up of melanoma patients
    Claus Garbe
    Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    Recent Results Cancer Res 160:205-15. 2002
    ....
  83. ncbi request reprint The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma
    Friedegund Meier
    Department of Dermatology, University of Tuebingen, Tuebingen, Germany
    Front Biosci 10:2986-3001. 2005
    ..The results of the research to date indicate that in melanoma both the MAPK and the AKT signaling pathways may represent promising therapeutic targets...
  84. ncbi request reprint Malignant blue naevus of the scalp
    Peter Radny
    Department of Dermatology, University of Tuebingen, Germany
    Lancet Oncol 5:429. 2004
  85. ncbi request reprint Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma
    Friedegund Meier
    Department of Dermatology, University of Tuebingen, Germany
    Exp Dermatol 12:296-306. 2003
    ..The described results of the current and previous studies emphasise the key role of FGF-2 in melanoma development and progression, underscoring the promise of FGF-2 as a target for therapy...
  86. doi request reprint Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    K Spieth
    Department of Dermatology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Ann Oncol 19:801-6. 2008
    ....
  87. ncbi request reprint The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions
    A Blum
    Department of Dermatology, University of Tuebingen, Liebermeisterstrasse 25, 72076 Tuebingen, Germany
    Br J Dermatol 149:1159-64. 2003
    ..The dermoscopic classification is a useful tool for handling patients with atypical naevi (Clark naevi)...
  88. ncbi request reprint Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma
    B Hoersch
    Department of Dermatology, Eberhard Karls University, Liebermeisterstrasse 25, D 72076 Tuebingen, Germany
    Br J Dermatol 155:771-7. 2006
    ..Therefore, cutaneous malignant melanoma (CMM) of the head and neck area is proposed to have notable differences from melanoma at other body sites regarding clinicopathological features and survival of patients...
  89. ncbi request reprint Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
    D Schadendorf
    Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Department of Dermatology, Mannheim, Germany
    Ann Oncol 17:1592-7. 2006
    ..The purpose of this study was to test a dose-intensified regimen of temozolomide in melanoma patients with brain metastases in a prospective, open-label, multicentre phase II trial...
  90. ncbi request reprint "Functional" surgery in subungual melanoma
    Matthias Moehrle
    Department of Dermatology, University of Tuebingen, Tuebingen, Germany
    Dermatol Surg 29:366-74. 2003
    ..Recently, we introduced for acral melanomas, similar to lentigo maligna melanoma, limited excision and complete histology of excisional margins (three-dimensional histology)...
  91. ncbi request reprint Continuous long-term monitoring of UV radiation in professional mountain guides reveals extremely high exposure
    Matthias Moehrle
    Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
    Int J Cancer 103:775-8. 2003
    ..These extremely high exposure values are suggestive for an increased risk of skin cancer and thorough epidemiologic studies in the collectives of professional and recreational mountaineering are required...
  92. ncbi request reprint Detection of dermcidin-derived peptides in sweat by ProteinChip technology
    Thomas Flad
    Section for Transplantation Immunology and Immunohaematology, University of Tuebingen, Waldhoernlestr 22, 72072, Tuebingen, Germany
    J Immunol Methods 270:53-62. 2002
    ..Such studies could reveal valuable new biomarkers for diagnosis and treatment of skin and sweat gland disorders...
  93. ncbi request reprint [Brief guidelines: Basal cell carcinoma of the skin]
    Helmut Breuninger
    Universitäts Hautklinik, D 72076 Tubingen
    J Dtsch Dermatol Ges 4:441-3. 2006
  94. ncbi request reprint Plasmid DNA- and messenger RNA-based anti-cancer vaccination
    Benjamin Weide
    Department of Dermatology, University of Tubingen, Liebermeisterstrasse 25, Tubingen, Germany
    Immunol Lett 115:33-42. 2008
    ..Combining optimized MNAV formulations and parallel adjuvant treatments could allow to turn MNAV-based vaccines into efficient anti-tumor immunotherapies in humans...
  95. ncbi request reprint [Brief guidelines: squamous cell carcinoma of the skin, lip and eyelids]
    Helmut Breuninger
    Universitäts Hautklinik Tübingen
    J Dtsch Dermatol Ges 4:260-2. 2006
  96. ncbi request reprint Dermatofibrosarcoma protuberans--an update
    Helmut Breuninger
    Universitäts Hautklinik Tübingen
    J Dtsch Dermatol Ges 2:661-7. 2004
    ..Re-excision of tumor-positive areas until tumor-free margins are obtained ("histographic surgery") insures a high cure rate (97%) while preserving normal tissue...
  97. ncbi request reprint [Brief guidelines--dermatofibrosarcoma protuberans]
    Helmut Breuninger
    Universitäts Hautklinik Tübingen
    J Dtsch Dermatol Ges 4:684-5. 2006
  98. ncbi request reprint Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma
    H J Blaheta
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany
    J Invest Dermatol 114:637-42. 2000
    ..These data may have an impact on future tumor classifications of primary cutaneous melanoma...
  99. ncbi request reprint Does mountaineering increase the incidence of cutaneous melanoma? A hypothesis based on cancer registry data
    M Moehrle
    Section of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tubingen, Germany
    Dermatology 199:201-3. 1999
    ....
  100. ncbi request reprint Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness
    H J Blaheta
    Department of Dermatology, Skin Cancer Programme, Eberhard Karls University, Liebermeister Str 25, 72076 Tubingen, Germany
    Br J Dermatol 145:195-202. 2001
    ..Tyrosinase reverse transcription-polymerase chain reaction (RT-PCR) has been shown to be highly sensitive in detecting tumour cells in melanoma patients...
  101. doi request reprint [Skin cancer in organ transplant patients. Epidemiology and management]
    U Leiter
    Zentrum für Dermato Onkologie, Universitäts Hautklinik, Eberhard Karls Universitat Tubingen, Liebermeisterstr 25, 72076, Tubingen
    Hautarzt 61:207-13. 2010
    ..The management of the individual tumor types is discussed; in general it follows the current guidelines...